Nine-valent HPV vaccine expands to women at 9-45 years old. Listening to medical experts, why should they "relax" age?

HPV vaccine is expanded.

On the evening of August 30, the official website of Merissa East announced that its nine -valent papilloma virus vaccine (brewing yeast), referred to as the "nine -valent HPV vaccine", has been approved by the National Drug Administration of China. The applicable crowd of Meridas' HPV vaccine has expanded to women 9-45 years old. At this point, the four-valent and nine-valent HPV vaccine under Merida East will jointly build a more solid healthy guardian for women in China, which are 9-45 years old, to further help more women in the age of HPV infection, including cervical cancer.

The nine -valent HPV vaccine uses a three -dose immunity, which is suitable for preventing HPV 16, 18, 31, 33, 45, 52, and 58 cervical cancer; HPV 6, 11, 16, 18, 31, 45, 52 and 52 and 52 and 52 and 52 Cervical epithelial tumor -like lesions (CIN1/2/3) caused by type 58 and cervical adenocarcinoma (AIS); and HPV 6, 11, 16, 18, 31, 33, 52, and 58 type 58 Continuous infection.

Cervical cancer is one of the common gynecological malignant tumors. In 2021, ICO/IARC's HPV and related diseases in China show that in 2020, among women 15-44 years old in China, the incidence and mortality rate of cervical cancer ranks third in female tumors. In China, about 98%of cervical cancer is caused by high -risk HPV. Although HPV16 and 18 are high -risk HPVs that are widely popular worldwide, there are differences in epidemiological research in China. Type HPVs are HPV 16, 52, and 58.

Professor Qiao Youlin of the School of Medicine and Public Health of the School of Medicine and Public Health of the Chinese Academy of Medical Sciences pointed out that young girls inocus HPV vaccines can easily stimulate better immune responses. Women who have not occurred in sex will have the best prevention effect. With the increase of age, women's ability to remove new hair and previous HPV infections decreases, which is more likely to lead to the risk of HPV's continuous infection and cervical cancer. Studies have shown that for women who have already occurred in sex, vaccination HPV vaccine also has a good protective effect.

"In order to reduce the threat of cervical cancer to women's health, in recent years, my country has attached great importance to the work related to the comprehensive prevention and control of women's cervical cancer. We can see that the quadrimal HPV vaccine was approved by a 9-45-year-old woman in China in 2020. The vaccination rate of the key population in my country has provided more help to promote the first prevention of cervical cancer. "Professor Qiao Youlin said," Today, the nine -valent HPV vaccine is approved to expand. Female -level women prevent HPV infection and reduce the risk of related diseases to bring more choices to protect health, and further promote the pace of accelerating the elimination of cervical cancer. "

At present, some outpatient clinics have begun to "ask" online.

Dr. Li Zhengqing, a senior vice president of Merhadon and President of Merck China R & D Center, said: "The expansion of the nine -valent HPV vaccine indication certificate is another important milestone for Merhadon to promote the innovation of vaccine research and development. Vaccine companies, for many years, based on strict clinical research and a large amount of real world data, have continuously discovered the potential of HPV vaccines to prevent various diseases in different populations. We currently carry out clinical research on many new indications of HPV vaccine in China. I hope that in the future, it can help more people benefit as soon as possible and escort the health of the Chinese public. "

Anna Van Acker, a senior vice president of Merhadon and President of Merck, said: "Eliminating cervical cancer is the common vision of all mankind, and Meridon is committed to protecting the health of Chinese women through cutting -edge vaccine products. The expansion of the age shows the determination of the Chinese government to accelerate the elimination of cervical cancer, and also add new help to Merck's support for China's cervical cancer prevention and control. Merhadon will continue to work closely with the government, society, business partners and all parties in the society to expand the global world to expand the global Measures such as production capacity and increased supply in the Chinese market, continuously enhance the accessibility of the HPV vaccine, support the development of China's public health, and join hands to welcome a future without cervical cancer. "

Source: Wen report

Edit: Wang Jing

- END -